Please login to the form below

Not currently logged in
Email:
Password:

Eloxatin

This page shows the latest Eloxatin news and features for those working in and with pharma, biotech and healthcare.

Sanofi predicts return to growth in second half

Sanofi predicts return to growth in second half

Sanofi is still weathering the effects of patent losses in 2012 for antiplatelet drug Plavix (clopidogrel), Avapro (irbesartan) for high blood pressure and cancer therapy Eloxatin (oxaliplatin) which collectively lost

Latest news

More from news
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics